Penumbra (NYSE:PEN) Announces Earnings Results

Penumbra (NYSE:PEN) issued its quarterly earnings results on Tuesday. The company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.09, Zacks reports. Penumbra had a net margin of 2.97% and a return on equity of 8.99%. Penumbra updated its FY 2025 guidance to EPS.

Penumbra Trading Up 0.9 %

Shares of NYSE:PEN traded up $2.32 during trading on Tuesday, hitting $270.99. 711,992 shares of the company’s stock were exchanged, compared to its average volume of 480,734. Penumbra has a 1-year low of $148.00 and a 1-year high of $277.89. The firm has a 50-day moving average price of $255.58 and a two-hundred day moving average price of $225.29. The company has a current ratio of 5.82, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The firm has a market cap of $10.40 billion, a P/E ratio of 315.10, a PEG ratio of 1.92 and a beta of 0.53.

Insider Transactions at Penumbra

In other news, EVP Johanna Roberts sold 600 shares of Penumbra stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $244.49, for a total transaction of $146,694.00. Following the completion of the sale, the executive vice president now owns 63,444 shares in the company, valued at $15,511,423.56. The trade was a 0.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Adam Elsesser sold 15,000 shares of Penumbra stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $237.28, for a total transaction of $3,559,200.00. Following the sale, the chief executive officer now owns 852,582 shares of the company’s stock, valued at approximately $202,300,656.96. This represents a 1.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,219 shares of company stock worth $7,985,639 in the last quarter. 5.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Citigroup raised their price objective on shares of Penumbra from $220.00 to $245.00 and gave the stock a “neutral” rating in a report on Wednesday, December 11th. Robert W. Baird lifted their price target on shares of Penumbra from $244.00 to $248.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Piper Sandler lifted their price target on shares of Penumbra from $235.00 to $250.00 and gave the company an “overweight” rating in a report on Wednesday, November 20th. UBS Group started coverage on shares of Penumbra in a report on Tuesday, January 21st. They set a “buy” rating and a $305.00 price target for the company. Finally, BTIG Research lifted their price target on shares of Penumbra from $232.00 to $270.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $261.36.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.